UK Markets closed

Gain Therapeutics, Inc. (GANX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.00-0.05 (-0.62%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.05
Open8.06
Bid7.75 x 1000
Ask10.50 x 1100
Day's range7.96 - 8.16
52-week range7.64 - 17.93
Volume5,188
Avg. volume29,217
Market cap95.013M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est30.00
  • Globe Newswire

    Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference

    BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 9 – 10. BTI

  • What Percentage Of Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Do Insiders Own?

    A look at the shareholders of Gain Therapeutics, Inc. ( NASDAQ:GANX ) can tell us which group is most powerful...

  • Globe Newswire

    Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders

    Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage DiseasesBETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced the publication of two PCT patents. PCT/IB2020/061158 and PCT/IB2020/0611156 are directed at compounds targeting misfold